FDA Approves Nivolumab/Ipilimumab Combination in Intermediate- or Poor-Risk Advanced RCC

On April 16, 2018, the U.S. Food and Drug Administration (FDA) granted approvals to nivolumab (Opdivo) and ipilimumab (Yervoy) in combination for the treatment of intermediate- or poor-risk previously untreated advanced renal cell carcinoma (RCC).

CheckMate 214

The approvals were based on CheckMate 214, a randomized open-label trial. Patients with previously untreated advanced RCC received nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks for 4 doses followed by nivolumab monotherapy (3 mg/kg) every 2 weeks, or sunitinib (Sutent) at 50 mg daily for 4 weeks followed by 2 weeks off every cycle.

Efficacy was evaluated in intermediate- or poor-risk patients (n = 847). The trial demonstrated statistically significant improvements in overall survival and objective response rate for patients receiving the combination (n = 425) compared with those receiving sunitinib (n = 422). Estimated median overall survival was not estimable in the combination arm compared with 25.9 months in the sunitinib arm (hazard ratio = 0.63, 95% confidence interval [CI] = 0.44–0.89; P < .0001). The objective response rate was 41.6% (95% CI = 36.9%–46.5%) for the combination vs 26.5% (95% CI = 22.4%–31%) in the sunitinib arm (P < .0001). The efficacy of the combination in patients with previously untreated RCC with favorable-risk disease was not established.

The most common adverse reactions (reported in at least 20% of patients treated with the combination) were fatigue, rash, diarrhea, musculoskeletal pain, pruritus, nausea, cough, pyrexia, arthralgia, and decreased appetite.

The recommended schedule and dose for this combination is nivolumab at 3 mg/kg followed by ipilimumab at 1 mg/kg, on the same day every 3 weeks for 4 doses, then nivolumab at 240 mg, every 2 weeks or 480 mg every 4 weeks.

Prescribing information for both nivolumab and ipilimumab have been updated with these results. Full prescribing information is available at:

The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.


Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.